Summary

Global Opioid Use Disorder Drugs Market was valued at USD 3.87 Billion in 2024 and is expected to reach USD 6.59 Billion in the forecast period with a CAGR of 9.26% through 2030. The Global Opioid Use Disorder Drugs Market is a dynamic and critical segment within the broader pharmaceutical industry, dedicated to addressing the escalating crisis of opioid addiction worldwide. With opioid abuse and overdose-related deaths reaching alarming levels, this market plays a pivotal role in providing effective solutions to combat this public health crisis. Opioid Use Disorder (OUD) drugs encompass a range of pharmaceutical interventions designed to treat addiction to opioids, including prescription painkillers and illicit substances like heroin. These medications typically fall into three categories: opioid agonists, partial agonists, and antagonists, each with its unique mechanism of action. Key drugs within this market include methadone, buprenorphine, naltrexone, and naloxone, which are administered in various forms such as oral tablets, sublingual films, or injectables.
Key Market Drivers
Escalating Opioid Epidemic
The escalating opioid epidemic has significantly influenced the Global Opioid Use Disorder (OUD) Drugs Market, reshaping the pharmaceutical landscape in response to this pressing public health crisis. This crisis, marked by the widespread misuse of prescription opioids and the proliferation of illicit substances like heroin, has led to devastating consequences, including a substantial number of opioid-related deaths. According to provisional data from the Centers for Disease Control and Prevention (CDC), there were an estimated 107,543 drug overdose deaths in the United States during 2023, with approximately 81,083 involving opioids. As communities confront the severe impacts of addiction, the demand for effective treatments has surged, creating opportunities for pharmaceutical companies to develop, market, and distribute a range of OUD drugs.
The opioid epidemic has unfolded on a global scale, transcending geographical and demographic boundaries. Governments, healthcare organizations, and the public have recognized the urgency of addressing this crisis comprehensively. This collective awareness has spurred significant investments in addiction treatment programs and policies aimed at expanding access to OUD drugs. However, challenges remain. In 2021, an estimated 2.5 million people aged 18 years or older in the U.S. had opioid use disorder, yet only 22% received medications to treat it. Addressing such gaps is crucial for mitigating the epidemic's impact. Furthermore, advancements like extended-release formulations have made treatment more convenient for patients, contributing to improved adherence and outcomes. As healthcare professionals and policymakers continue to grapple with the opioid crisis, the pharmaceutical industry remains pivotal in developing innovative medications to effectively treat OUD.
Key Market Challenges
Regulatory Complexity
One of the primary challenges is the lack of uniformity in regulations across different regions and countries. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and counterparts in other nations, have unique guidelines and requirements for OUD medications. This variation can lead to confusion and increased compliance costs for pharmaceutical companies operating internationally. The opioid epidemic is a rapidly evolving crisis, and regulatory agencies often struggle to keep pace with emerging trends and challenges. This lag in adapting regulations can hinder the timely approval of new medications and treatment modalities, impeding the market's ability to respond effectively to the crisis.
OUD medications, including opioid agonists like methadone and buprenorphine, are subject to strict regulations surrounding their prescription and dispensing. Healthcare providers must undergo specialized training and obtain waivers to prescribe these medications, creating barriers to access. Furthermore, stringent record-keeping requirements and oversight can deter providers from offering these treatments. Some OUD medications are subject to Risk Evaluation and Mitigation Strategies, which impose additional requirements on manufacturers and healthcare providers. While these strategies are intended to enhance the safe use of medications, they can also increase the administrative burden and costs associated with bringing OUD drugs to market.
Key Market Trends
Expansion of Medication-Assisted Treatment (MAT)
One of the most significant trends in the OUD Drugs Market is the increasing adoption of Medication-Assisted Treatment (MAT). MAT combines pharmacotherapy, such as opioid agonists (e.g., methadone and buprenorphine), with counseling and behavioral therapies to address opioid addiction comprehensively. MAT is now widely recognized as the gold standard of care for OUD, and its expansion has significantly boosted the market. Increased Access to Treatment: MAT programs have proliferated, making treatment more accessible to individuals grappling with OUD. The availability of MAT in a variety of healthcare settings, including specialized clinics, primary care offices, and even pharmacies, has broadened the reach of OUD treatment. MAT has demonstrated its effectiveness in reducing opioid misuse, promoting long-term recovery, and preventing opioid overdose deaths. As more individuals have access to MAT, better treatment outcomes become achievable, leading to increased confidence in these therapies.
Key Market Players
• Mallinckrodt Pharmaceuticals
• Hikma Pharmaceuticals Inc
• Collegium Pharmaceutical, Inc.
• Braeburn, Inc.
• Purdue Pharma L.P.
• Curia Global Inc.
• EMERGENT
• Bristol-Myers Squibb, S.r.l
• Alkermes, Inc.
• Indivior Inc.
Report Scope:
In this report, the Global Opioid Use Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Opioid Use Disorder Drugs Market, By Drug Type:
o Agonist Drugs
o Antagonist Drugs
o Others
• Opioid Use Disorder Drugs Market, By Route of Administration:
o Oral
o Parenteral
o Sublingual
o Nasal
• Opioid Use Disorder Drugs Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Opioid Use Disorder Drugs Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Opioid Use Disorder Drugs Market.
Available Customizations:
Global Opioid Use Disorder Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Opioid Use Disorder Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type (Agonist Drugs, Antagonist Drugs, Others)
5.2.2. By Route of Administration (Oral, Parenteral, Sublingual, Nasal)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.4. By Company (2024)
5.2.5. By Region
5.3. Market Map
6. North America Opioid Use Disorder Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Opioid Use Disorder Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Mexico Opioid Use Disorder Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Canada Opioid Use Disorder Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. Europe Opioid Use Disorder Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Opioid Use Disorder Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. Germany Opioid Use Disorder Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Opioid Use Disorder Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Opioid Use Disorder Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Opioid Use Disorder Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Opioid Use Disorder Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Opioid Use Disorder Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Opioid Use Disorder Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. South Korea Opioid Use Disorder Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. Japan Opioid Use Disorder Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Opioid Use Disorder Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. South America Opioid Use Disorder Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Opioid Use Disorder Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina Opioid Use Disorder Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia Opioid Use Disorder Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Opioid Use Disorder Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Opioid Use Disorder Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia Opioid Use Disorder Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. UAE Opioid Use Disorder Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. Competitive Landscape
15.1. Mallinckrodt Pharmaceuticals
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Hikma Pharmaceuticals Inc
15.3. Collegium Pharmaceutical, Inc.
15.4. Braeburn, Inc.
15.5. Purdue Pharma L.P.
15.6. Curia Global Inc.
15.7. EMERGENT
15.8. Bristol-Myers Squibb, S.r.l
15.9. Alkermes, Inc.
15.10. Indivior Inc.
16. Strategic Recommendations
17. About Us & Disclaimer